The role of tumour markers and biomarkers in colorectal cancer

Neoplasma

Volumn 61, Issue 1, 2014, Pages 1-8

  Lech, G ^a   Slotwinski, R ^a,b   Krasnodebski, I W ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Biomarker; Carcinoembryonic antigen CEA; Chromosome 18q loss of heterozygosity; Colorectal cancer; Colorectal cancer biomarkers; KRAS mutation; Microsatellite instability; PIK3CA mutation; Tumor marker; Tumour marker

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CA 242 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EZRIN; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; UGT1A1 ENZYME;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CHROMOSOME 18Q; CHROMOSOME DELETION; COLORECTAL CANCER; DIARRHEA; DNA POLYMORPHISM; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; MICROSATELLITE INSTABILITY; NEUTROPENIA; PHENOTYPIC VARIATION; PLOIDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; BLOOD; COLORECTAL TUMOR; DRUG ANTAGONISM; GENETICS; MUTATION; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS;

CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; GLUCURONOSYLTRANSFERASE; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE INSTABILITY; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84893206517     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_003     Document Type: Review

References (70)

1. LABIANCA R, NORDLINGER B, BERETTA GD, BRONQUET A, CERVANTES A. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010; 21: 70-77. http://dx.doi.org/10.1093/annonc/mdq168
2. BERRINO F, DE ANGELIS R, SANT M, ROSSO S, BIELSKALASOTA M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773-783. http://dx.doi.org/10.1016/S1470-2045(07)70245-0
3. GOLD P, FREEDMAN SO. Demonstration of tumor specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439-462. http://dx.doi.org/10.1084/jem.121.3.439
4. PALMQVIST R, ERGARAS B, LINDMARK G, HALLMANS G, TAVELIN B et al. Prediagnostic levels of carcinoembryonic antigen and CA 242 in colorectal cancer: A matched case-control study. Dis Colon Rectum 2003; 46: 538-544. http://dx.doi.org/10.1007/s10350-004-6810-z
5. LOCKER GY, HAMILTON S, HARRIS J, JESSUP JM, KEMENY N et al. American Society of Clinical Oncology 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer. J Clin Oncol 2006; 24: 5313-5327. http://dx.doi.org/10.1200/JCO.2006.08.2644
6. DUFFY MJ, VAN DALEN A, HAGLUND C, HANSSON L, KLAPDOR R et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumor Markers (EGTM) guidelines. Eur J Cancer 2003; 39: 718-727. http://dx.doi.org/10.1016/S0959-8049(02)00811-0
7. CHEN CC, YANG SH, LIN JK, LIN TC, CHEN WS et al. Is it reasonable to add preoperative serum level of CEA and CA 19-9 to staging for colorectal cancer? J Surg Res 2005; 124: 369-374.
8. WEISSENBERGER C, VON PLEHN G, OTTO F, BARKE A, MOMM F et al. Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: Role of CEA and CA 19-9. Anticancer Res 2005; 25: 1787-1793.
9. PARK YJ, YOUK EG, CHOI HS, HAN SU, PARK KJ et al. Experience of 1446 rectal cancer patients in Korea and analysis of prognostic factors. Int J Colorectal Dis 1999; 14: 101-106. http://dx.doi.org/10.1007/s003840050193
10. PARK YJ, PARK KJ, PARK JG, LEE KU, CHOE KJ et al. Prognostic factors in 2230 Korean colorectal cancer patients: Analysis of consecutively operated cases. World J Surg 1999; 23: 721-726. http://dx.doi.org/10.1007/PL00012376
11. COMPTON C, FENOGLIO-PREISER CM, PETTIGREWN, FIELDING LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 8: 1739-1757. http://dx.doi.org/10.1002/(SICI)1097-0142(20000401)88:7<1739::AIDCNCR30>3.0.CO;2-T
12. THIRUNAVUKARASU P, SUKUMAR S, SATHAIAH M, MAHAN M, PRAGATHEESHWAR KD et al. C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst 2011; 103: 689-697. http://dx.doi.org/10.1093/jnci/djr078
13. UENO H, MOCHIZUKI H, HATSUSE K, HASE K, YAMAMOTO T. Indicators for treatment strategies of colorectal liver metastases. Ann Surg 2000; 231: 59-66. http://dx.doi.org/10.1097/00000658-200001000-00009
14. MALA T, BOHLER G, MATHISEN O, BERGAN A, SOREIDE O. Hepatic resection for colorectal metastases: Can preoperative scoring predict patient outcome? World J Surg 2002; 26: 1348-1353. http://dx.doi.org/10.1007/s00268-002-6231-x
15. GOLDSTEIN MJ, MITCHELL EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005; 23: 338-351. http://dx.doi.org/10.1081/CNV-58878
16. GRAHAM RA, WANG S, CATALANO PJ, HALLER DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg 1998; 228: 59-63. http://dx.doi.org/10.1097/00000658-199807000-00009
17. SCHMOLL HJ, VAN CUTSEM E, STEIN A, VALENTINI V, GLIMELIUS B et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Onc 2012; 23: 2479-2516. http://dx.doi.org/10.1093/annonc/mds236
18. NICOLINI A, FERRARI P, DUFFY MJ, ANTONELLI A, ROSSI G et al. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences. Effect on survival. Arch Surg 2010; 145: 1177-1183. http://dx.doi.org/10.1001/archsurg.2010.251
19. CARPELAN-HOLMSTROM M, LOUHIMO J, STENMAN UH, ALFTHAN H, JARVINEN H et al. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Tumor Biol 2004; 25: 228-234. http://dx.doi.org/10.1159/000081385
20. LUMACHI F, MARINO F, ORLANDO R, CHIARA GB, BASSO SM. Simultaneous multianalyte immunoassay measurement of five serum tumor markers in the detection of colorectal cancer. Anticancer Res 2012; 32: 985-988.
21. LEVY M, VISOKAI V, LIPSKA L, TOPOLCAN O. Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma 2008; 55: 138-142.
22. MARRELLI D, CARUSO S, NERI A, PEDRAZZANI C, CAPUANO L et al. Clinical utility of serum tumor markers in the diagnosis of malignant intestinal occlusion. A prospective observational study. Int J Biol Markers 2011; 26: 58-64. http://dx.doi.org/10.5301/JBM.2011.6284
23. BABA Y, NOSHO K, SHIMA K, IRAHARA N, KURE S et al. Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia 2009; 11: 418-425.
24. BOLAND CR, THIBODEAU SN, HAMILTON SR, SIDRANSKY D, ESHLEMAN JR et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257.
25. POPAT S, HUBNER R, HOULSTON RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-618. http://dx.doi.org/10.1200/JCO.2005.01.086
26. GRYFE R, KIM H, HSIEH ET, ARONSON MD, HOLOWATY EJ et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69-77. http://dx.doi.org/10.1056/NEJM200001133420201
27. SAMOWITZ WS, CURTIN K, MA KN, SCHAFFER D, COLEMAN LW et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001; 10: 917-923.
28. RIBIC CM, SARGENT DJ, MOORE MJ, THIBODEAU SN, FRENCH AJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349; 247-257. http://dx.doi.org/10.1056/NEJMoa022289
29. KIM GP, COLANGELO LH, WIEAND HS, PAIK S, KIRSCH IR et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007; 25: 767-772. http://dx.doi.org/10.1200/JCO.2006.05.8172
30. SINICROPE FA, SARGENT DJ. Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 2009; 21: 369-373. http://dx.doi.org/10.1097/CCO.0b013e32832c94bd
31. MEYERS M, WAGNER MW, HWANG HS, KINSELLA TJ, BOOTHMAN DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001; 61: 5193-5201.
32. CARETHERS JM, CHAUHAN DP, FINK D, NEBEL S, BRESALIER RS et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. 'Gastroenterology 1999; 117: 123-131. http://dx.doi.org/10.1016/S0016-5085(99)70558-5
33. ELSALEH H, IACOPETTA B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001; 1: 104-109. http://dx.doi.org/10.3816/CCC.2001.n.010
34. ELSALEH H, POWELL B, MCCAUL K, GRIEU F, GRANT R et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001; 7: 1343-1349.
35. ELSALEH H, JOSEPH D, GRIEU F, ZEPS N, SPRY N et al. Association of tumor site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355: 1745-1750. http://dx.doi.org/10.1016/S0140-6736(00)02261-3
36. BERTAGNOLLI MM, NIEDZWIECKI D, COMPTON CC, HAHN HP, HALL M et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009; 27: 1814-1821. http://dx.doi.org/10.1200/JCO.2008.18.2071
37. SARLI L, BOTTARELLI L, BADER G, IUSCO D, PIZZI S et al. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q. Dis Colon Rectum 2004; 47: 1467-1482. http://dx.doi.org/10.1007/s10350-004-0628-6
38. POPAT S, HOULSTON RS. A systematic review and metaanalysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005; 41: 2060-2070. http://dx.doi.org/10.1016/j.ejca.2005.04.039
39. POPAT S, ZHAO D, CHEN Z, PAN H, SHAO Y et al. Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients. Anticancer Res 2007; 27: 627-633.
40. OGINO S, NOSHO K, IRAHARA N, SHIMA K, BABA Y et al. Prognostic significance and molecular associations of 18q loss of heterozygosity: A cohort study of microsatellite stable colorectal cancers. J Clin Oncol 2009; 27: 4591-4598. http://dx.doi.org/10.1200/JCO.2009.22.8858
41. WATANABE T, WU TT, CATALANO PJ, UEKI T, SATRIANO R et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-1206. http://dx.doi.org/10.1056/NEJM200104193441603
42. WATANABE T, KOBUNAI T, YAMAMOTO Y, MATSUDA K, ISHIHARA S et al. Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer. J Clin Oncol 2012; 30: 2256-2264. http://dx.doi.org/10.1200/JCO.2011.38.6490
43. http://clinicaltrials.gov/ct2/show/study/NCT00217737?term=ecog+5202&rank=1
44. DE ROOCK W, JONKER DJ, DI NICOLANTONIO F, SARTORE-BIANCHI A, TU D et al. Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812-1820. http://dx.doi.org/10.1001/jama.2010.1535
45. SALAHSHOR S, KRESSNER U, PAHLMAN L, GLIMELIUS B, LINDMARK G et al. Colorectal cancer with and without microsatellite instability involves different genes. Genes Chromosomes Cancer 1999; 26: 247-252. http://dx.doi.org/10.1002/(SICI)1098-2264(199911)26:3<247::AIDGCC9>3.0.CO;2-H
46. MARKOWITZ SD, BERTAGNOLLI MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-2460. http://dx.doi.org/10.1056/NEJMra0804588
47. DI FIORE F, BLANCHARD F, CHARBONNIER F, LE PESSOT F, LAMY A et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169. http://dx.doi.org/10.1038/sj.bjc.6603685
48. LIEVRE A, BACHET JB, BOIGE V, CAYRE A, LE CORRE D et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379. http://dx.doi.org/10.1200/JCO.2007.12.5906
49. VAN CUTSEM E, KOHNE CH, LANG I, FOLPRECHT G, NOWACKI MP et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019. http://dx.doi.org/10.1200/JCO.2010.33.5091
50. BOKEMEYER C, CUTSEM EV, ROUGIER P, CIARDIELLO F, HEEGER S et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48; 1466-1475. http://dx.doi.org/10.1016/j.ejca.2012.02.057
51. TEJPAR S, CELIK I, SCHLICHTING M, SARTORIUS U, BOKEMEYER C et al. Association of KRAS G13d tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-3577. http://dx.doi.org/10.1200/JCO.2012.42.2592
52. DI NICOLANTONIO F, MARTINI M, MOLINARI F, SARTORE-BIANCHI A, ARENA S et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712. http://dx.doi.org/10.1200/JCO.2008.18.0786
53. ROTH AD, TEJPAR S, DELORENZI M, YAN P, FIOCCA R et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474. http://dx.doi.org/10.1200/JCO.2009.23.3452
54. SOOD A, MCCLAIN D, MAITRA R, BASU-MALLICK A, SEETHARAM R et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer 2012; 11: 143-150. http://dx.doi.org/10.1016/j.clcc.2011.12.001
55. OGINO S, NOSHO K, KIRKNER GJ, SHIMA K, IRAHARA N et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. 2009; 27: 1477-1484.
56. LIAO X, MORIKAWA T, LOCHHEAD P, IMAMURA Y, KUCHIBA A et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012; 18: 2257-2268. http://dx.doi.org/10.1158/1078-0432.CCR-11-2410
57. JHAWER M, GOEL S, WILSON A J, MONTAGNA C, LING YH et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68: 1953-1961. http://dx.doi.org/10.1158/0008-5472.CAN-07-5659
58. SARTORE-BIANCHI A, MARTINI M, MOLINARI F, VERONESE S, NICHELATTI M et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies. Cancer Res 2009; 69: 1851-1857. http://dx.doi.org/10.1158/0008-5472.CAN-08-2466
59. DE ROOCK W, CLAES B, BERNASCONI D, DE SCHUTTER J, BIESMANS B et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762. http://dx.doi.org/10.1016/S1470-2045(10)70130-3
60. LIAO X, LOCHHEAD P, NISHIHARA R, MORIKAWA T, KUCHIBA A et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367: 1596-1606. http://dx.doi.org/10.1056/NEJMoa1207756
61. SHULMAN K, COHEN I, BARNETT-GRINESS O, KUTEN A, GRUBER SB et al. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer 2011; 117: 3156-3162. http://dx.doi.org/10.1002/cncr.25735
62. DIAS MM, MCKINNON RA, SORICH MJ. Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. Pharmacogenomics 2012; 13: 889-899. http://dx.doi.org/10.2217/pgs.12.68
63. BYSTROM P, BERGLUND A, NYGREN P, WERNROTH L, JOHANSSON B et al. Evaluation of predictive markers for patients with advanced colorectal cancer. Acta Oncol 2012; 51: 849-859. http://dx.doi.org/10.3109/0284186X.2012.705020
64. HOLDENRIEDER S, STIEBER P, LISKA V, TRESKA V, TOPOLCAN O et al. Cytokeratin serum biomarkers in patients with colorectal cancer. Anticancer Res 2012; 32: 1971-1976.
65. PATARA M, MONTEIRO SANTOS EM, DE ALMEIDA COUDRY R, SOARES FA, FERREIRA FO et al. Ezrin expression as a prognostic marker in colorectal adenocarcinoma. Pathol Oncol Res 2011; 17: 827-833. http://dx.doi.org/10.1007/s12253-011-9389-4
66. JORGREN F, NILBERT M, RAMBECH E, BENDAHL PO, LINDMARK G. Ezrin expression in recital cancer predicts time to development of local recurrence. Int J Colorectal Dis 2012; 27: 893-899. http://dx.doi.org/10.1007/s00384-011-1397-z
67. CHEN WS, CHANG HY, LI CP, LIU JM, HUANG TS. Tumor β-1,4-galactosyltransferaze iv overexpression is closely associated with colorectal cancer metastasis and poor prognosis. Clin Cancer Res 2005; 11: 8615-8622. http://dx.doi.org/10.1158/1078-0432.CCR-05-1006
68. LENZ HJ. Established biomarkers for colon cancer. In: American Society of Clinical Oncology 2009 Educational Book. ASCO, 2009: 215-219.
69. ELLIS LM. Promising future biomarkers for colorectal cancer. In: American Society of Clinical Oncology 2009 Educational Book. ASCO, 2009: 212-214.
70. ENGSTROM PF, ARNOLETTI JP, BENSON AB, CHEN YI, CHOTI MA et al. Colon Cancer Clinical practice guidelines in oncology. JNCCN 2009; 7: 778-831.